About Agenovir
Agenovir is a Healthcare company based in San Francisco (United States) founded in 2014, and was acquired by Vir Biotechnology in May 2018. It operates as an antiviral therapeutics are developed using nuclease-based technologies for infectious diseases. Agenovir has raised $10.6 million across 2 funding rounds from investors including Lightspeed Venture Partners, Vir Biotechnology and HHS. The company was acqui-hired. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its legal entity is Agenovir Corporation. Its competitors include Moderna, BridgeBio, Adaptive Biotechnologies, Spark Therapeutics and Alnylam and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Agenovir was established in 2014 in San Francisco, United States, within the biotechnology sector. Focus is placed on creating antiviral therapeutics targeting infectious diseases tied to latent or persistent viral reservoirs. CRISPR-Cas9 and other nucleases are employed to target and remove pathogenic viral DNA inside cells. Development efforts center on innovative gene-editing methods to address viral persistence.
- Headquarters San Francisco, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website agenovir.com
- Acquired by Vir Biotechnology (May 2018)
- Legal Name Agenovir Corporation
- Total Equity Funding$10.6M (USD)
in 2 rounds
- Latest Funding Round$10.6M (USD), Series A
May 2016
- InvestorsLightspeed Venture Partners
& 4 more
- Acquired byVir Biotechnology
(May 2018)
Funding Insights of Agenovir
Agenovir has successfully raised a total of $10.6M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $10.6 million completed in May 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.6M
- Total Rounds 2
- Last Round Series A — $10.6M
- First Round $136,773
(Jan 2016)
- Investors Count 4
All 2 funding rounds of Agenovir with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
5 investors in total: 5 institutional.
Investors in Agenovir
Agenovir has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Lightspeed Venture Partners, Vir Biotechnology and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on multiple sectors | – | dcvc.com | Palo Alto, United States | |
Venture capital investing in innovative companies across global sectors is undertaken by Lightspeed Venture Partners. | 1997 | lsvp.com | Menlo Park, United States | |
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Developer of therapeutics for the treatment of infectious diseases | 2017 | vir.bio | San Francisco, United States |
Investor details for Agenovir
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Agenovir
91 people are tracked at Agenovir (59 in leadership, 8 in board & advisors, 24 in team).
| Name | Role | Group |
|---|---|---|
Dezz Ropp | Vice President, Program And Portfolio Management | Leadership |
Jacqueline McBride | Vice President, Translational Biology At Vir Biotechnology, Inc. | Leadership |
Maryam Sadat | Senior Vice President Quality, EHS & Lab Ops | Leadership |
Tyler Chuang | Associate Director, Research Strategic Planning And Operations | Leadership |
Vladimir N. Podust | Senior Director, Analytical And Formulation Development / QC Oncology | Leadership |
Sandy Deveze | Head Of Clinical Data Management | Leadership |
James L. | Senior Director, Tax | Leadership |
Grace Jiang | Head Of Regulatory Affairs, Oncology, VP | Leadership |
Cailey Ruth | Director | Leadership |
Maribel Reyes | Vp, Clinical Pharmacology | Leadership |
Amy Rock | Senior Vice President, Regulatory Affairs | Leadership |
Kevin Anglim | Director, Compensation | Leadership |
Tim Hwang | Vice President, Human Resources | Leadership |
Leah Anderson Gaffney | Director Clinical Research | Leadership |
Hung Truong | Associate Director, Procurement Research Lead | Leadership |
Marianne De Backer | CEO | Leadership |
Mimmi Ballard | Director, Analytical Development And Quality Control, Bioassays | Leadership |
Jeff Calcagno | Executive Vice President & Chief Business Officer | Leadership |
Tammy Diehl | Associate Director, Project Management Oncology | Leadership |
Tamara Palagashvili | Sr. Medical Director, Medical Affairs | Leadership |
71 more people are available in the full profile.
Complete people profiles for Agenovir
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Agenovir
4 dated milestones of Agenovir across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Agenovir is founded.
- Funding First funding round of $137K.
- Funding Latest funding round, Series A, of $10.6M.
- Exit Acquired by Vir Biotechnology.
Competitors of Agenovir
Agenovir has 9 listed competitors in our database, 9 of them funded. They include Moderna, BridgeBio, Adaptive Biotechnologies, Spark Therapeutics and Alnylam, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of Agenovir
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Agenovir (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Agenovir
Complete news archive for Agenovir
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Agenovir
Agenovir was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Agenovir is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Agenovir is a funded company, having raised a total of $10.6M across 2 funding rounds to date. The company's 1st funding round was a Grant of $136.77K, raised on Jan 2016.
Agenovir was established in 2014 in San Francisco, United States, within the biotechnology sector. Focus is placed on creating antiviral therapeutics targeting infectious diseases tied to latent or persistent viral reservoirs. CRISPR-Cas9 and other nucleases are employed to target and remove pathogenic viral DNA inside cells. Development efforts center on innovative gene-editing methods to address viral persistence.
Agenovir's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Agenovir has 5 investors. Key investors include Lightspeed Venture Partners, Vir Biotechnology, HHS, Celgene, and DCVC.
Agenovir operates through Agenovir Corporation.
Yes. Agenovir was acquired by Vir Biotechnology in May 2018.